Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Anal Cancer Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Anal Cancer Overview | 8 | 1 |
| Pipeline Products for Anal Cancer Comparative Analysis | 9 | 1 |
| Anal Cancer Therapeutics under Development by Companies | 10 | 1 |
| Anal Cancer Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Anal Cancer Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Anal Cancer Products under Development by Companies | 14 | 1 |
| Anal Cancer Products under Investigation by Universities/Institutes | 15 | 1 |
| Anal Cancer Companies Involved in Therapeutics Development | 16 | 12 |
| Advaxis, Inc. | 16 | 1 |
| Amgen Inc. | 17 | 1 |
| Cell Medica Limited | 18 | 1 |
| Eli Lilly and Company | 19 | 1 |
| Genticel S.A. | 20 | 1 |
| ISA Pharmaceuticals B.V. | 21 | 1 |
| Novartis AG | 22 | 1 |
| Ono Pharmaceutical Co., Ltd. | 23 | 1 |
| Oryx GmbH &Co. KG | 24 | 1 |
| PDS Biotechnology Corporation | 25 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 26 | 1 |
| Taiwan Liposome Company, Ltd. | 27 | 1 |
| Anal Cancer Therapeutics Assessment | 28 | 9 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 66 |
| axalimogene filolisbac Drug Profile | 37 | 16 |
| Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 53 | 1 |
| CMD-004 Drug Profile | 54 | 1 |
| GTL-001 Drug Profile | 55 | 3 |
| ISA-101 Drug Profile | 58 | 3 |
| nivolumab Drug Profile | 61 | 28 |
| paclitaxel albumin free Drug Profile | 89 | 1 |
| panitumumab Drug Profile | 90 | 5 |
| PDR-001 Drug Profile | 95 | 1 |
| PDS-0101A Drug Profile | 96 | 2 |
| prexasertib Drug Profile | 98 | 2 |
| TLC-388 Drug Profile | 100 | 2 |
| Vicoryx Drug Profile | 102 | 1 |
| Anal Cancer Dormant Projects | 103 | 1 |
| Anal Cancer Product Development Milestones | 104 | 10 |
| Featured News &Press Releases | 104 | 1 |
| Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer | 104 | 1 |
| Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer | 104 | 2 |
| Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac | 106 | 1 |
| Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer | 106 | 1 |
| Dec 07, 2015: ISA Pharmaceuticals ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab | 106 | 1 |
| Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold | 107 | 1 |
| Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer | 108 | 1 |
| Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer | 108 | 1 |
| Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience | 109 | 1 |
| Sep 16, 2013: ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia | 109 | 1 |
| Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV | 110 | 1 |
| Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV | 111 | 1 |
| Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy | 111 | 1 |
| Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer | 112 | 2 |
| Appendix | 114 | 2 |
| Methodology | 114 | 1 |
| Coverage | 114 | 1 |
| Secondary Research | 114 | 1 |
| Primary Research | 114 | 1 |
| Expert Panel Validation | 114 | 1 |
| Contact Us | 114 | 1 |
| Disclaimer | 115 | 1 |